Positive preliminary results for Cellectar Biosciences

Cellectar Biosciences Inc. (Nasdaq: CLRB) reported positive results from a preliminary tumor-targeting study of CLR 1602 sending the stock price up 52 cents to $3.82.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.